| Literature DB >> 24250270 |
Marius A Scheepers1, Karin A Lecuona, Graeme Rogers, Catey Bunce, Craig Corcoran, Michel Michaelides.
Abstract
OBJECTIVE: To assess the value of routine polymerase chain reaction (PCR) analysis on intraocular fluid from patients presenting with a first episode of suspected active infectious posterior uveitis in a population with a high prevalence of human immunodeficiency virus infection.Entities:
Mesh:
Year: 2013 PMID: 24250270 PMCID: PMC3819945 DOI: 10.1155/2013/545149
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Patient characteristics.
| Mean age | 34 (range 14–53) |
| Gender | |
| Male | 58 |
| Female | 101 |
| Laterality | |
| Bilateral | 67 |
| Right eye | 42 |
| Left eye | 50 |
| HIV +ve | 142 |
| HAART treatment at presentation | 65 |
| MTB treatment at presentation | 67 |
HIV: human immunodeficiency virus.
HAART: highly active antiretroviral treatment.
Average visual acuities (VA) pre- and post-treatment.
| Pre-treatment | Post-treatment | |
|---|---|---|
| VA ≥ 6/18 | 42% | 33% |
| VA 6/24–4/60 | 16% | 14% |
| VA ≤ 3/60 | 42% | 53% |
| Eyes assessed | 226 | 191 |
Thirty-five eyes were lost to followup (due to patients defaulting followup before completion of treatment).
PCR tests performed.
| Infectious agent | Number tests perf. | Number +ve | % +ve |
|---|---|---|---|
| CMV | 154 | 72 | 47% |
| TG | 150 | 12 | 8% |
| VZV | 148 | 17 | 11% |
| HSV | 148 | 0 | 0% |
| MTB | 43 | 1 | 2% |
|
| |||
| Total tests | 643 | 102 | 16% |
Pre-PCR clinical diagnoses correlated with PCR positive results.
| Pretest diagnoses | Number | CMV | VZV | HSV | TG | MTB | CMV & VZV | CMV & TG | PCR +ve | |
|---|---|---|---|---|---|---|---|---|---|---|
| +ve | +ve | +ve | +ve | +ve | +ve | +ve | Rate number | % | ||
| CMV | 70 | 51 | 4 | 4 | 1 | 60 | 86% | |||
| NHR | 14 | 3 | 2 | 3 | 2 | 10 | 71% | |||
| TG | 10 | 1 | 1 | 2 | 20% | |||||
| MTB | 7 | 1 | 1 | 14% | ||||||
| Syphilis | 5 | 0 | 0% | |||||||
| IRU | 2 | 0 | 0% | |||||||
| Unsure | 51 | 11 | 5 | 3 | 1 | 1 | 21 | 41% | ||
|
| ||||||||||
| Total | 159 | 66 | 11 | 0 | 11 | 1 | 4 | 1 | 94 | 59% |
IRU: immune reconstitution uveitis.
Final diagnoses.
| CMVR | 74 |
| NHR | 17 |
| OT | 16 |
| MTB | 5 |
| Syphilis | 4 |
| CMV/VZV coinfection | 2 |
| HIV-associated retinopathy | 2 |
| Toxocariasis | 1 |
| Immune reconstitution uveitis | 1 |
| Blood dyscrasia | 2 |
| Idiopathic or end-stage late presentation | 35 |
Estimated sensitivity, specificity, positive predictive value, and negative predictive value for each pathogen tested and broken down into AC and vitreous samples.
| Sample number | True +ve | False +ve | True −ve | False −ve | Sens | Spec | PPV | NPV | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CMV | 154 | 69 | 45% | 1 | 1% | 74 | 48% | 7 | 5% | 91% | 99% | 99% | 91% |
| AC | 45 | 13 | 29% | 0 | 0% | 31 | 69% | 1 | 2% | 93% | 100% | 100% | 97% |
| V | 106 | 56 | 53% | 1 | 1% | 43 | 41% | 6 | 6% | 90% | 98% | 98% | 88% |
| NS | 3 | 2 | 67% | 0 | 0% | 1 | 33% | 0 | 0% | — | — | — | — |
| VZV | 148 | 15 | 10% | 2 | 1% | 126 | 85% | 5 | 3% | 75% | 98% | 88% | 96% |
| AC | 43 | 1 | 2% | 0 | 0% | 39 | 91% | 3 | 7% | 25% | 100% | 100% | 93% |
| V | 102 | 14 | 14% | 2 | 2% | 84 | 82% | 2 | 2% | 88% | 98% | 88% | 98% |
| NS | 3 | 0 | 0% | 0 | 0% | 3 | 100% | 0 | 0% | — | — | — | — |
| TOXO | 150 | 12 | 8% | 0 | 0% | 134 | 89% | 4 | 3% | 75% | 100% | 100% | 97% |
| AC | 45 | 1 | 2% | 0 | 0% | 43 | 96% | 1 | 2% | 50% | 100% | 100% | 98% |
| V | 102 | 11 | 11% | 0 | 0% | 88 | 86% | 3 | 3% | 79% | 100% | 100% | 97% |
| NS | 3 | 0 | 0% | 0 | 0% | 3 | 100% | 0 | 0% | — | — | — | — |
| MTB | 43 | 1 | 2% | 0 | 0% | 39 | 91% | 3 | 7% | 25% | 100% | 100% | 93% |
| AC | 20 | 1 | 5% | 0 | 0% | 16 | 80% | 3 | 15% | 25% | 100% | 100% | 84% |
| V | 22 | 0 | 0% | 0 | 0% | 22 | 100% | 0 | 0% | 0% | — | — | 100% |
| NS | 1 | 0 | 0% | 0 | 0% | 1 | 100% | 0 | 0% | — | — | — | — |
|
| |||||||||||||
| Total | 495 | 97 | 20% | 3 | 1% | 373 | 75% | 19 | 4% | 84% | 99% | 97% | 95% |
AC: anterior chamber; V: vitreous; NS: not specified; Sens: sensitivity; Spec: specificity; PPV: positive predictive value; NPV: negative predictive value.
(1) Three patients had samples taken from an unknown site (not specified in the clinical notes).
(2) Simultaneous vitreous and aqueous sampling was performed on 4 patients.
(3) Two patients had repeat sampling (both were vitreous sample repeats).
Comparison of estimated sensitivity, specificity, positive predictive value, and negative predictive value for specimen sites.
| Sample number | True +ve | False +ve | True −ve | False −ve | Sens | Spec | PPV | NPV | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AC | 153 | 16 | 10% | 0 | 0% | 129 | 84% | 8 | 5% | 67% | 100% | 100% | 94% |
| V | 332 | 81 | 24% | 3 | 1% | 237 | 71% | 11 | 3% | 88% | 99% | 96% | 96% |
| NS | 10 | 2 | 20% | 0 | 0% | 8 | 80% | 0 | 0% | — | — | — | — |
|
| |||||||||||||
| Total | 495 | 97 | 20% | 3 | 1% | 373 | 75% | 19 | 4% | 84% | 99% | 97% | 95% |
AC: anterior chamber; V: vitreous; NS: not specified; Sens: sensitivity; Spec: specificity; PPV: positive predictive value; NPV: negative predictive value.
(1) Three patients had samples taken from an unknown site (not specified in the clinical notes).
(2) Simultaneous vitreous and aqueous sampling was performed on 4 patients.
(3) Two patients had repeat sampling (both were vitreous sample repeats).